|
2025
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases,... |
|
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of cancer |
|
|
Invention
|
Quinazolines as potassium ion channel inhibitors.
A compound of formula I
A compound of formul... |
|
|
Invention
|
Process for the preparation of a cyclic dinucleotide.
The invention generally relates to an impr... |
|
|
Invention
|
Anti-lag-3 antibodies to treat hematological malignancies.
Provided are methods for clinical tre... |
|
|
Invention
|
Methods of treating cancer with antibodies against tim3.
This disclosure provides a method for t... |
|
|
Invention
|
Antisense oligonucleotides targeting alpha-synuclein and uses thereof.
The present disclosure re... |
|
|
Invention
|
Tim-3 antagonists for the treatment and diagnosis of cancers.
Provided herein are methods for tr... |
|
|
Invention
|
Methods of producing recombinant proteins.
In certain embodiments, this disclosure provides nove... |
|
|
Invention
|
Compounds and their use for treatment of hemoglobinopathies.
Disclosed herein are compounds and ... |
|
|
Invention
|
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors.
Provided are meth... |
|
|
Invention
|
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an... |
|
|
Invention
|
Methods of treating urothelial carcinoma using an anti-pd-1 antibody.
This disclosure provides a... |
|
|
Invention
|
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti... |
|
|
Invention
|
Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment.
This inven... |
|
|
Invention
|
Methods to manipulate quality attributes of polypeptides produced in cho cells.
In accordance wi... |
|
|
Invention
|
Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody... |
|
|
Invention
|
Cytokine profiling analysis.
This invention relates to methods for predicting a prognosis of a p... |
|
|
Invention
|
Ligand directed degrader of irak4. Provided herein is a compound of the following structural form... |
|
|
Invention
|
Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds (I) and... |
|
|
Invention
|
Methods of treating a tumor using an anti-pd-1 antibody.
This disclosure provides a method for t... |
|
2024
|
Invention
|
Combination therapy of kras inhibitor and treg depleting agent.
In some aspects, the present dis... |
|
|
Invention
|
Combination therapy of kras inhibitor and treg-depleting agent. In some aspects, the present disc... |
|
|
Invention
|
Antibodies targeting il-18 receptor beta (il-18rb) and related methods.
Provided are novel antib... |
|
|
Invention
|
Antibodies targeting il-18 receptor beta (il-18rβ) and related methods. Provided are novel antibo... |
|
|
Invention
|
Wee1 degrading compounds and uses thereof. Provided herein are compounds and compositions thereof... |
|
|
Invention
|
Leveraging large language models for automating lines of therapy adjudication in cancer patients.... |
|
|
Invention
|
Wee1 degrading compounds and uses thereof.
Provided herein are compounds and compositions thereo... |
|
|
Invention
|
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use.
Disclosed herein ... |
|
|
Invention
|
Substituted heterocyclic compounds.
There are disclosed compounds of the following formula I:
... |
|
|
Invention
|
Kras g12c inhibitors. The present disclosure provides KRAS inhibitors of formula (I). Methods of ... |
|
|
Invention
|
Antibodies binding to vista at acidic ph.
The present application relates to antibodies specific... |
|
|
Invention
|
Machine-learning models for prognosing outcomes for hypertrophic cardiomyopathy (hcm). A computer... |
|
|
Invention
|
Machine-learning models for prognosing outcomes for hypertrophic cardiomyopathy (hcm).
A compute... |
|
|
Invention
|
2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1... |
|
|
Invention
|
2-(4-(2-(7,8-dimethyl-[l,2,4jtriazolo[l,5-a]pyridin-6-yl)-3-isopropyl- lh-indol-5-yl)piperid!n-l-... |
|
|
Invention
|
Ubiquitin specific processing protease 1 (usp1) compounds. Compounds having the following formula... |
|
|
Invention
|
Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)pheny... |
|
|
Invention
|
Kras inhibitors.
The present disclosure provides KRAS inhibitors. Methods of treating cancers us... |
|
2023
|
Invention
|
Pharmaceutical compositions for improving oral bioavailability.
In accordance with the present d... |
|
|
Invention
|
Methods of isolating polypeptides.
The present disclosure is directed methods of isolating and/o... |
|
|
Invention
|
Transient expression of therapeutic proteins.
The present disclosure provide novel methods of la... |
|
|
Invention
|
Combination therapy for colorectal carcinoma.
The invention provides a method of treating a colo... |
|
|
Invention
|
Substituted imidazopyridinyl compounds useful as inhibitors of tlr9.
Disclosed are compounds of ... |
|
|
Invention
|
Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9.
Disclosed are compounds ... |
|
|
Invention
|
Combination therapy for hepatocellular carcinoma.
The disclosure provides a method of treating a... |
|
2022
|
Invention
|
Macrocyclic immunomodulators.
In accordance with the present disclosure, macrocyclic compounds h... |
|
|
Invention
|
Rxfp1 agonists.
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor ago... |
|
|
Invention
|
2,3-dihydrobenzo[b][1,4]dioxin-6-yl containing compounds useful as immunomodulators.
The present... |
